文献速递免疫规划慢病防控与筛查卫生政策与健康促进

更新的人口学、伤残权重与宫颈癌负担对全球、区域及国家层面人乳头瘤病毒疫苗接种影响估计的作用:一项PRIME模型研究

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
PubMed 文献 · Lancet Glob Health · 2020-02-24

研究更新PRIME模型的人口学、伤残权重和宫颈癌负担数据,估计177个国家9岁和12岁女孩接种二价/四价或九价HPV疫苗的健康影响。更新后每1000名接种女孩避免的病例、死亡和DALY分别增加26%、51%和72%。HPV疫苗接种的健康收益和成本效果优于先前估计,WHO非洲区域收益最大。

要点

  • 更新后二价/四价疫苗每1000名接种女孩避免15例病例、12例死亡和243个DALY。
  • 九价疫苗每1000名接种女孩避免19例病例、14例死亡和306个DALY。
  • 12岁女孩接种的健康收益与9岁女孩相似但略低。

核心结论

  • HPV疫苗接种提供的健康收益比先前估计更大且更具成本效果。
  • 人口学更新(纳入人口老龄化)对健康影响估计的影响最大。
  • WHO非洲区域预计获得最大健康收益,应优先开展HPV疫苗接种。

研究设计与样本

  • 使用PRIME模型,纳入联合国世界人口展望2019年修订版人口学数据、全球疾病负担2017年研究伤残权重和GLOBOCAN 2018宫颈癌负担数据。
  • 估计177个国家9岁和12岁女孩在2020-29年期间接种二价/四价或九价HPV疫苗、覆盖率达90%的终身健康收益。
  • 健康影响以每1000名接种女孩避免的宫颈癌病例、死亡或DALY表示,并与无接种的反事实情景比较。

主要发现

  • 对9岁女孩接种的估计中,人口学、伤残权重和宫颈癌负担估计的联合更新使每1000名接种女孩避免的病例数增加26%、死亡数增加51%、DALY增加72%,二价/四价和九价疫苗均如此。
  • 更新模型估计二价/四价HPV疫苗每1000名接种女孩避免15例病例、12例死亡和243个DALY。
  • 更新模型估计九价HPV疫苗每1000名接种女孩避免19例病例、14例死亡和306个DALY。
  • 12岁女孩接种的健康收益与9岁女孩相似但略低。

临床怎么用

  • WHO非洲区域预计获得最大健康收益,应优先开展HPV疫苗接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) has been used around the world to assess the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls. We updated PRIME with new data and methods for demography, disability weights, and cervical cancer burden, and generated revised estimates of the health impact of HPV vaccination at the global, regional, and national levels for 177 countries. METHODS: PRIME was updated with population demography of the UN World Population Prospects (UNWPP) 2019 revision, disability weights of the Global Burden of Disease (GBD) 2017 study, and cervical cancer burden from the Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018 database. We estimated the lifetime health benefits for bivalent or quadrivalent and nonavalent vaccination of 9-year-old and 12-year-old girls at 90% coverage during 2020-29 in 177 countries. Health impact was presented in terms of cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000 vaccinated girls in comparison with the counterfactual scenario of no vaccination, and the number of girls needed to be vaccinated to prevent a single case, death, or DALY. FINDINGS: In estimating the health impact of HPV vaccination of 9-year-old girls, the combined updates to demography, disability weights, cervical cancer burden estimates resulted in a 26% increase in the estimated number of cases averted, a 51% increase in deaths averted, and a 72% increase in DALYs averted per 1000 vaccinated girls for both the bivalent or quadrivalent and nonavalent vaccines, compared with previous estimates. With the updated model, the bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases, 12 deaths, and 243 DALYs per 1000 vaccinated girls, and the nonavalent HPV vaccine was estimated to avert 19 cases, 14 deaths, and 306 DALYs per 1000 vaccinated girls. The health benefits of vaccination of 12-year-old girls were estimated to be similar but slightly decreased in comparison with vaccination of 9-year-old girls. INTERPRETATION: HPV vaccination provides greater health benefits and is more cost-effective than was previously estimated. The demography update, which incorporates population aging, has the largest effect on the health impact estimates. The WHO African region is expected to gain the greatest health benefits and should be prioritised for HPV vaccination. FUNDING: Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Abbas KM, van Zandvoort K, Brisson M, et al. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. Lancet Glob Health. 2020. PMID: 32105613. doi:10.1016/S2214-109X(20)30022-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。